| payload |
{"created_at":"2026-04-07T03:18:43.308 {"created_at":"2026-04-07T03:18:43.308311+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:0f072cc71fa28b97","evidence_event_ids":["evt_52810f149f2e"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000149.txt","as_of":"2026-04-07T03:18:43.308311+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000149.txt","company":"Cartesian Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000149.txt","article_chars":3120,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_aa49e6dc5791ee39","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000149.txt","content_type":"text/plain","enriched_at":"2026-04-07T10:22:18.964673+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000149.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000149.txt","source_event_id":"evt_52810f149f2e","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"3c39a1d53bdce42d","kind":"sec_filing","published_at":"20260406","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["2026-04-02","2026-04-06","2023-11-13"],"entities":[{"asset_class":"equity","name":"Cartesian Therapeutics, Inc.","relevance":"issuer","symbol":"CRTX","type":"company"}],"event_type":"listing","information_gaps":["No specific number of shares remaining after conversion provided.","Details on the beneficial ownership limitation are not specified."],"key_facts":["Filing date: April 6, 2026","Form type: 4","Reporting owner: Seven One Eight Three Four Irrevocable Trust","Conversion of Series A Non-Voting Convertible Preferred Stock into common stock on April 2, 2026."],"numeric_claims":[{"label":"Shares converted","value":"758001"},{"label":"Remaining shares subject to limitation","value":"22740.03"}],"primary_claim":"The Seven One Eight Three Four Irrevocable Trust converted a portion of its Series A Non-Voting Convertible Preferred Stock into common stock of Cartesian Therapeutics, Inc.","relevance_score":0.8,"sentiment":"neutral","source_quality":"high","summary":"Cartesian Therapeutics, Inc. filed a Form 4 indicating changes in beneficial ownership related to the conversion of Series A Non-Voting Convertible Preferred Stock into common stock by the Seven One Eight Three Four Irrevocable Trust.","topics":["SEC Filing","Ownership Change","Convertible Securities"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Cartesian Therapeutics, Inc. \u00b7 Filed 20260406","ticker":"RNAC","tickers":["RNAC"],"title":"RNAC filed 4","url":"https://www.sec.gov/Archives/edgar/data/1453687/0002064832-26-000149.txt"}}... |